Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer
NCT05902533Phase 3Active, not recruiting
- Sponsor
- University of Cincinnati
- Start
- Aug 2023
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial in anal cancer, sponsored by University of Cincinnati. Primary endpoints: Toxicity Index for GI, GU, Dermatologic, and Hematologic CTCAE events and Patient reported GI toxicity using PRO-CTCAE Diarrhea. Started Aug 2023; status: active, not recruiting.
02
Conditions
anal cancer
Beyond the preview
Go deeper on NCT05902533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05902533.